PRISM BioLab206A東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

What does PRISM BioLab do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

※ Operating cash flow is negative

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥833.7M

Operating cash flow-¥1.47B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥1.47B

Free cash flow-¥1.54B

Net income-¥833.7M

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (2)

EDINET (FSA Japan)
有価証券報告書－第14期(2024/10/01－2025/09/30)
ID S100XCIN2025-12-24Open
EDINET (FSA Japan)
有価証券報告書－第13期(2023/10/01－2024/09/30)
ID S100V11F2024-12-27Open

Extracted from XBRL: 36 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.